United States

Neuren Pharmaceuticals Ltd (NEU.AX)

NEU.AX on Australia Stock Exchange

13 Dec 2017
Change (% chg)

$0.09 (+3.09%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Chart for


Neuren Pharmaceuticals Limited (Neuren) is a biopharmaceutical company engaged in developing drugs for neurological disorders. The Company develops therapies for brain injury, neurodevelopmental and neurodegenerative disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic... (more)


Beta: 0.78
Market Cap(Mil.): $298.02
Shares Outstanding(Mil.): 99.34
Dividend: --
Yield (%): --


  Industry Sector
P/E (TTM): -- 188.50 15.25
EPS (TTM): -- -- --
ROI: -- -11.67 33.27
ROE: -- -36.21 16.35

BRIEF-Neuren Pharmaceuticals posts HY net loss attributable of $3.6 mln

* HY net loss attributable to members $3.6 million versus loss of $7.4 million Source text for Eikon: Further company coverage:

Aug 24 2017

BRIEF-Neuren Pharmaceuticals secures funding for key activities for Rett syndrome

* Secured funding to enable initiation of key activities on critical path for commencing a phase 3 trial in rett syndrome

Jun 28 2017

BRIEF-Neuren Pharmaceuticals requests trading halt

* Seeks trading halt pending an announcement regarding a capital raising transaction Source text for Eikon: Further company coverage:

Jun 27 2017

Earnings vs. Estimates